Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 28:5:183-186.
doi: 10.1016/j.pmedr.2016.12.023. eCollection 2017 Mar.

Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015

Mark Stuntz  1 , Brent Bernstein  1
Affiliations

Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015

Mark Stuntz et al. Prev Med Rep. .

Abstract

Aspirin therapy has been shown to be an effective prevention measure to reduce the risk of new or recurring cardiovascular events. The aim of this study was to provide an epidemiological analysis of low-dose aspirin use for primary and secondary CVD prevention from 2012 to 2015. Estimates of self-reported low-dose aspirin use for primary and secondary CVD prevention were obtained from the National Health Interview Survey for the years 2012-2015. Temporal changes in the prevalence of aspirin use for primary and secondary CVD prevention were assessed using logistic regression. During 2012-2015, 23.3% of respondents self-reported as taking aspirin for primary CVD prevention, decreasing from 23.7% in 2012 to 21.8% in 2015. Also during this period, 8.4% self-reported as taking aspirin for secondary CVD prevention, decreasing from 8.9% in 2012 to 8.2% in 2015. Overall, the prevalence of aspirin use for CVD prevention declined from 32.6% in 2012 to 30.0% in 2015. This study shows that over 30% of the adult population self-reports as taking low-dose aspirin for primary or secondary CVD prevention. Despite the decline in this prevalence over the previous four years, aspirin therapy remains a highly-utilized means of preventing CVD.

Keywords: Aspirin; Cardiovascular disease; Epidemiology.

PubMed Disclaimer

References

    1. Baigent C., Blackwell L., Collins R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860. - PMC - PubMed
    1. Bibbins-Domingo K., US Preventive Services Task Force Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 2016;164:836–845. - PubMed
    1. Bieler G.S., Brown G.G., Williams R.L., Brogan D.J. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am. J. Epidemiol. 2010;171:618–623. - PubMed
    1. Centers for Disease Control and Prevention Questionnaire Design Research Laboratory. 2016. http://www.cdc.gov/qdrl/ (Available from, 6 September)
    1. Fang J., George M.G., Gindi R.M. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012) Am. J. Cardiol. 2015;115:895–900. - PMC - PubMed

LinkOut - more resources